Fig. 4: Vaccine dose-down studies refine logistic model based on GP-binding antibody levels for immunobridging.
a EBOV GP-binding antibody concentrations (EU/mL, log10 transformed) as determined by FANG ELISA (BBRC); group means are indicated; dotted line is LOD. b Table identifies dose of Ad26.ZEBOV and MVA-BN-Filo with highest dose represented in green and lowest dose in red. Vaccine dose interval is 8 weeks. An overview by regimen can be found in Supplementary Table 4. c Logistic regression models of GP-binding antibodies as predictor of survival after EBOV Kikwit challenge (100 pfu, IM) in NHP for all vaccine regimens combined from five NHP studies (red), all regimens combined from seven NHP studies (blue), Ad26.ZEBOV, MVA-BN-Filo regimen with an 8-week interval only (green). Individual immune response levels are identified with open circles and the associated survival as a binary variable with survival as 1 (top) and nonsurvival as 0 (bottom). Assay LOD is indicated by dotted line. d ROC curves for sensitivity and specificity of GP-binding antibody levels in predicting NHP survival after challenge for all vaccine regimens combined from five NHP studies (red), all regimens combined from seven NHP studies (blue), Ad26.ZEBOV, MVA-BN-Filo regimen with an 8-week interval only (green). ROC AUC are indicated in the panel. BBRC Battelle Biomedical Research Institute, ELISA enzyme-linked immunosorbent assay, EU ELISA units, FANG Filovirus Animal Non-Clinical Group, InfU infectious units, vp viral particles.
